NRSN News

NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

NeuroSense Provides Update on Nasdaq Listing Compliance

NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

NeuroSense Provides Business Update and Progress for the First Half of 2026

NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference

NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS

NeuroSense Issues CEO Letter to Shareholders

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS